{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:14:29Z","timestamp":1772558069944,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128227","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T12:42:45Z","timestamp":1768653765000},"page":"128227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center"],"prefix":"10.1016","volume":"75","author":[{"given":"L.","family":"Yesenia Rodr\u00edguez-Tanta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Delgado-Escalante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"del Pilar Solis-Yucra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique Cachay","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisela Alva","family":"Lozada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz E.","family":"Veramendi-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Espinoza-Ildefonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Saromo-Mel\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00eds","family":"Lazarte-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Aldave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela Milla","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Garcia","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Renter\u00eda","family":"Valdiviezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor E.","family":"Lechuga-Noa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128227_bb0005","article-title":"Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment","volume":"36","author":"Naniche","year":"2021","journal-title":"eClinicalMedicine [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128227_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128227_bb0015","doi-asserted-by":"crossref","unstructured":"Klungel O, Potteg\u00e5rd A. Strengthening international surveillance of vaccine safety | The BMJ [Internet]. Available from: https:\/\/www.bmj.com\/content\/374\/bmj.n1994.long.","DOI":"10.1136\/bmj.n1994"},{"key":"10.1016\/j.vaccine.2026.128227_bb0020","unstructured":"Organization WH. Global vaccine safety blueprint. 2012; Available from: https:\/\/iris.who.int\/handle\/10665\/70919."},{"issue":"40","key":"10.1016\/j.vaccine.2026.128227_bb0025","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2020.07.013","article-title":"Planning for COVID-19 vaccines safety surveillance","volume":"38","author":"Kochhar","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128227_bb0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-020-01002-6","article-title":"Assessing the safety of COVID-19 vaccines: a primer","volume":"43","author":"Petousis-Harris","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128227_bb0035","unstructured":"Ministerio de Salud. Documento t\u00e9cnico: Plan nacional de vacunaci\u00f3n contra la COVID-19 [internet]. 2020. Available from: https:\/\/bvs.minsa.gob.pe\/local\/fi-admin\/rm-848-2020.pdf."},{"key":"10.1016\/j.vaccine.2026.128227_bb0040","doi-asserted-by":"crossref","unstructured":"Haider T, Abidi SRZ, Fatima M, Zafar A, Siddiqui RQU, Khan W, et al. The Prevalence of Side Effects of Sinopharm COVID-19 Vaccine: An Experience From Pakistan. Cureus. 15(4):e38180. doi:https:\/\/doi.org\/10.7759\/cureus.38180.","DOI":"10.7759\/cureus.38180"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128227_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/vaccines11010105","article-title":"Adverse effects of Sinopharm COVID-19 vaccine among vaccinated medical students and health care workers","volume":"11","author":"Meo","year":"2023","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128227_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00284-023-03432-8","article-title":"Adverse effects reported and insights following Sinopharm COVID-19 vaccination","volume":"80","author":"Mohebbi","year":"2023","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.vaccine.2026.128227_bb0055","unstructured":"AEFI [Internet]. Available from: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/aefi."},{"key":"10.1016\/j.vaccine.2026.128227_bb0060","unstructured":"Pan American Health Organization. Consultation document for case definitions. Adverse Events of Special Interest, and Adverse Events Following Immunization during COVID-19 Vaccine Introduction [Internet]. 2022. Available from: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/55721\/PAHOHSSMTCOVID19210017_eng.pdf?sequence=4&isAllowed=y."},{"key":"10.1016\/j.vaccine.2026.128227_bb0065","unstructured":"Case definitions archives [internet]. Brighton Collaboration 2024. Available from: https:\/\/brightoncollaboration.org\/category\/case-definitions\/."},{"key":"10.1016\/j.vaccine.2026.128227_bb0070","unstructured":"Ministerie van Volksgezondheid W en S. Prof. Miriam Sturkenboom: ACCESS programme for large scale COVID-19 vaccine monitoring - Regulatory Science [Internet]. Ministerie van Volksgezondheid, Welzijn en Sport; Available from: https:\/\/www.regulatoryscience.nl\/editions\/2020\/11\/miriam-sturkenboom-access-program-for-large-scale-covid-19-vaccine-monitoring."},{"key":"10.1016\/j.vaccine.2026.128227_bb0075","unstructured":"AEFI\u00a0: Casualty Assessment Software [Internet]. Available from: https:\/\/gvsi-aefi-tools.org\/index.html."},{"key":"10.1016\/j.vaccine.2026.128227_bb0080","unstructured":"Seguro Social de Salud (EsSalud), Instituto de Evaluaci\u00f3n de Tecnolog\u00edas en Salud e Investigaci\u00f3n (IETSI), Seguro Social de Salud (EsSalud), Instituto de Evaluaci\u00f3n de Tecnolog\u00edas en Salud e Investigaci\u00f3n (IETSI). 2022 Microsoft Power BI. Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiNjZhNWM4OWItYzg4OS00ZDNkLTgzODItZTMzMWM2OGQwMDBmIiwidCI6IjM0ZjMyNDE5LTFjMDUtNDc1Ni04OTZlLTQ1ZDYzMzcyNjU5YiIsImMiOjR9."},{"key":"10.1016\/j.vaccine.2026.128227_bb0085","unstructured":"World Health Organization. Evidence Assessment: Sinopharm\/BBIBP COVID-19 vaccine [Internet]. 2021. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2021\/april\/2_sage29apr2021_critical-evidence_sinopharm.pdf."},{"key":"10.1016\/j.vaccine.2026.128227_bb0090","unstructured":"Programa Ampliado de, Inmunizaciones. Vigilancia de ESAVI. Relacionada a la vacunaci\u00f3n contra COVID-19 [Internet]. Paraguay: Ministerio de salud y bienestar social; 2021. Report No.: Boletin epidemiol\u00f3gico. Available from: https:\/\/pai.mspbs.gov.py\/wp-content\/uploads\/2021\/10\/19-Boletin-Epidemiologico-ESAVI.pdf."},{"key":"10.1016\/j.vaccine.2026.128227_bb0095","unstructured":"Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud \u2013 AGEMED. BOLET\u00cdN N\u00b01 A\u00d1O 2021 Esavi (Eventos supuestamente atribuibles a la vacunaci\u00f3n o inmunizaci\u00f3n) [Internet]. Bolivia: Ministerio de salud y deportes.; 2021. Available from: https:\/\/www.agemed.gob.bo\/archivos_agemed\/BOLETIN-ESTA-001-2021.pdf."},{"key":"10.1016\/j.vaccine.2026.128227_bb0100","unstructured":"Ministerio de Salud. Informe de seguridad en vacunas [Internet]. Argentina; 2021 Jan. Available from: https:\/\/www.argentina.gob.ar\/sites\/default\/files\/2023\/08\/informe_especial_de_vigilancia_de_seguridad_en_vacunas_en_ninios_ninas_adolescentes.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128227_bb0105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/vaccines10040488","article-title":"The side effects and adverse clinical cases reported after COVID-19 immunization","volume":"10","author":"Rabail","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128227_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13205-021-03076-0","article-title":"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review","volume":"12","author":"Simnani","year":"2022","journal-title":"3 Biotech"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128227_bb0115","article-title":"Safety and adverse events related to inactivated COVID-19 vaccines and Novavax;a systematic review","volume":"10","author":"Dadras","year":"2022","journal-title":"Arch Acad Emerg Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128227_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272729","article-title":"Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: a comparative study among healthcare professionals of Nepal","volume":"17","author":"Rayamajhi","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128227_bb0125","doi-asserted-by":"crossref","unstructured":"Li X, Yang X, Ning Z. Efficacy and safety of COVID-19 inactivated vaccine: A meta-analysis. Front Med (Lausanne). 2022. 9:1015184. Published 2022 Nov 7. doi:https:\/\/doi.org\/10.3389\/fmed.2022.1015184.","DOI":"10.3389\/fmed.2022.1015184"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128227_bb0130","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3390\/vaccines10101767","article-title":"Vaccine adverse events following COVID-19 vaccination with inactivated vaccines in Zimbabwe","volume":"10","author":"Makadzange","year":"2022","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128227_bb0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128227_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102207","article-title":"Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study","volume":"15","author":"Almufty","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.vaccine.2026.128227_bb0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","article-title":"Side effects and perceptions following Sinopharm COVID-19 vaccination","volume":"111","author":"Saeed","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128227_bb0150","first-page":"001","article-title":"Adverse events reported from the COVID-19 vaccines: a descriptive study based on the WHO database (VigiBase\u00ae)","volume":"11","author":"Dutta","year":"2021","journal-title":"J Appl Pharm Sci"},{"key":"10.1016\/j.vaccine.2026.128227_bb0155","article-title":"Survey of symptoms following COVID-19 vaccination in India [internet]","author":"Jayadevan","year":"2021","journal-title":"medRxiv"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128227_bb0160","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/jcm10122629","article-title":"Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare Workers in Turkey","volume":"10","author":"Riad","year":"2021","journal-title":"J Clin Med"},{"issue":"51","key":"10.1016\/j.vaccine.2026.128227_bb0165","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","article-title":"Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza a (H1N1) vaccines: reports to VAERS","volume":"31","author":"Halsey","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128227_bb0170","first-page":"408","article-title":"Sex and gender impact immune responses to vaccines among the elderly","volume":"30","author":"Fink","year":"2015","journal-title":"Physiol Bethesda Md"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128227_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S095026880100629X","article-title":"Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?","volume":"127","author":"Bayas","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128227_bb0180","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jinf.2014.08.018","article-title":"Incidence of herpes zoster and its complications in Germany, 2005-2009","volume":"70","author":"Hillebrand","year":"2015","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128227_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4236\/aar.2024.136009","article-title":"Adverse side effects of COVID-19 vaccines in older adults: a comprehensive review of current research","volume":"13","author":"Selbe","year":"2024","journal-title":"Adv Aging Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:49:30Z","timestamp":1772552970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S0264410X26000344"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128227","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128227"}}